Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 32 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

O-7111 Oxaliplatin, >99%       Prices Reduced (November 2011)

[Foloxatine] [Transplatin] [Eloxatin] [Eloxatine] [Elplat] [RP 54780] [Dacplat] [Oxalato(1R,2R-cyclohexanediamine)platinum(II)] [Oxalatoplatin] [Oxalatoplatinum]

M.W. 397.29

C8H14N2O4Pt

[61825-94-3]

M.I. 14:  6912

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in water at 4 mg/mL and DMSO at 20 mg/mL; very slightly soluble in methanol; insoluble in ethanol.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Oxaliplatin is a a third-generation, diaminocyclohexane-containing platinum anti-cancer drug.  It is typically used in combination with fluorouracil (5-FU) and leucovorin, known as FOLFOX, for the treatment of colorectal cancer.  The leucovorin-modulated single-agent 5-FU regimens achieved a median overall survival of 15 months or less.  Combination regimens of FOLFOX consistently lead to median survivals in the 15 to 20-month range.  Goldberg, R.M.  "Therapy for Metastatic Colorectal Cancer."  The Oncologist 11:  981-987 (2006).

• Oxaliplatin has different antitumor spectrum, mechanisms of action, and resistance from the other platinum-containing compounds, notably cisplatin.  Raymond, E., et al.  "Cellular and molecular pharmacology of oxaliplatin."  Mol. Cancer Ther. 1:  227-235 (2002).

• The anticancer activity and the antitumor specificity of oxaliplatin mainly depend on human organic cation transporters (OCT) 1 and OCT2.  Zhang, S., et al.  "Organic cation transporters are determinants of oxaliplatin cytotoxicity."  Cancer Res. 66:  8847-8857 (2006).

• The oxaliplatin cytotoxicity depends on MKK7/JNK, while SEK1 might be involved in hypoxic resistance to oxaliplatin.  Vasilevskaya, I.A., et al.  "Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin."  Mol. Pharmacol. 74:  246-254 (2008).

• Oxaliplatin is the active ingredient in the drug sold under the trade name Eloxatin®.  This drug has been approved in at least one country for use in patients with colorectal cancer.  NOTE:  The oxaliplatin sold by LC Laboratories is NOT Eloxatin®, and is NOT for human use.

• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.